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Abstract 
Detection and quantification of lysine degradation metabolites in plasma is necessary for the diagnosis and follow-
up of diseases such as pyridoxine-dependent epilepsy. The principal metabolites involved in the disease are related 
to the first steps of lysine oxidation, either through the saccharopine or the pipecolate pathways. Currently, there 
are three different analytical methods used to assess the content of these metabolites in urine and plasma, but they 
require different sample preparations and analytical equipment. Here, we describe a protocol that calls for a simple 
sample preparation and uses liquid chromatography tandem mass spectrometry (LC–MS/MS) that allows simultane-
ous detection and quantification of underivatized l-saccharopine, l-aminoadipic acid, l-pipecolic acid, piperideine-
6-carboxylate, l-glutamic acid, and pyridoxal-5-phosphate in plasma samples. To validate the method we analyzed the 
time course degradation after intraperitoneal injection of l-lysine in C57BL/6/J mice. We observed that the degrada-
tion of lysine through the saccharopine pathway reached a maximum within the first 2 h. At this time point there was 
an increase in the levels of the metabolites saccharopine, aminoadipic acid, and pipecolic acid by 3-, 24- and 3.4-fold, 
respectively, compared to time zero levels. These metabolites returned to basal levels after 4–6 h. In conclusion, we 
have developed a LC–MS/MS approach, which allows simultaneous analysis of lysine degradation metabolites with-
out the need for derivatization.
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Background
Lysine oxidation in mammals is essential for regulat-
ing the free levels of this amino acid, for the balance of 
nitrogen and conversion to ketone bodies. The saccharo-
pine pathway is considered the main route for irrevers-
ible degradation of lysine in higher eukaryotes (Carson 
et al. 1968; Blemings et al. 1994; Arruda et al. 2000). The 
first step of this pathway is catalyzed by lysine-ketoglu-
tarate reductase (LKR), which condenses lysine and 
α-ketoglutaric acid to form saccharopine (SAC) (Arruda 
et  al. 2000). The next step is catalyzed by saccharopine 
dehydrogenase (SDH), which hydrolyses saccharopine into 
glutamic acid (GLU) and α-aminoadipic-δ-semialdehyde 
(AASA) (Fig.  1). In animals and plants, the activities of 
LKR and SDH belong to distinct domains of a bifunc-
tional polypeptide called aminoadipic semialdehyde syn-
thase (AASS) that is encoded by the gene aass (Markovitz 
et  al. 1984; Goncalves-Butruille et  al. 1996; Papes et  al. 
1999). An additional pathway for lysine degradation exists 
in humans, the pipecolate pathway (Fig.  1) (Chang 1978; 
Hallen et al. 2013). The saccharopine and pipecolate path-
ways differ in the way lysine is oxidized and which nitro-
gen group is removed to form AASA. In the pipecolate 
pathway, lysine degradation occurs via α-deamination 
whereas in the saccharopine pathway the reaction involves 
a ε-deamination. In both cases, lysine is deaminated and 
oxidized to produce AASA, which spontaneously cyclizes 
into piperideine-6-carboxylate (P6C). Both of these 
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molecules function as substrates for the enzyme aminoadi-
pic semialdehyde dehydrogenase (AASADH), in a rapid 
reaction that gives rise to aminoadipic acid (AAA) (Fig. 1).
Metabolites derived from lysine oxidation have sgnifi-
cant implications in the pathophysiology of specific 
diseases such as pyridoxine-dependent epilepsy (PDE). 
PDE is caused by a mutation in the aldh7a1 gene that 
abolishes the AASADH activity and patients accumu-
late high levels of AASA/P6C and pipecolic acid (PIP) 
(Mills et al. 2006). Although there is a consensus that the 
Fig. 1 Schematic representation of lysine degradation pathways in mammals. Lysine can be degraded via pipecolate and saccharopine pathways. 
In the pipecolate pathway, that is believed to operate mostly in the brain, lysine is deaminated at the alpha nitrogen, and the resulted pipecolic acid 
is converted to P6C by pipecolate oxidase (PIPOX). In the saccharopine pathway that has been demonstrated in several tissues, lysine is deaminated 
at the epsilon nitrogen. In the first reaction step, catalyzed by the lysine-ketoglutarate reductase (LKR) domain of the aminoadipic semialdehyde 
synthase (AASS), lysine is condensed with α-ketoglutarate to form saccharopine. Than the saccharopine dehydrogenase (SDH) domain of AASS 
hydrolyse saccharopine into glutamic acid and α-aminoadipic-δ-semialdehyde (AASA). AASA is then oxidized to form aminoadipic acid (AAA) by the 
enzyme aminoadipic semialdehyde dehydrogenase (AASADH). AASA is in equilibrium with its cyclic form P6C. P6C can be used as substrate by the 
enzyme piperideine-5-carboxilic reductase (P5CR). AAA than proceeds to several enzymatic steps catalyzed by the enzymes AADAT (aminoadipate 
aminotransferase), DHTKD1 (dehydrogenase E1 and transketolase domain containing 1), GCDH (glutaryl-CoA dehydrogenase), ECHS1 (enoyl-CoA 
hydratase, short chain, 1), HADH (Hydroxyacyl-coenzyme A dehydrogenase) and ACAA2 (acetyl-CoA acyltransferase 2) to form acetyl-CoA. Muta-
tions in the genes encoding AASADH and GCDH lead to PDE and glutaric aciduria type 1 disease, respectively
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saccharopine pathway plays a significant role in lysine 
catabolism, especially in liver and kidney (Higashino 
et  al. 1971; Blemings et  al. 1994; Papes, et  al. 2001), 
recent reports have suggested that this pathway is virtu-
ally absent in the brain. Instead, the pipecolate pathway 
may be predominant in cerebral tissues, suggesting that 
this could be the target of choice for development of new 
therapeutic interventions (Sauer et al. 2011; Hallen et al. 
2013; Posset et  al. 2015). However, most of the experi-
ments conducted to verify the levels of saccharopine or 
the absence of AASS activity in cerebral tissues were per-
formed in mice without lysine supplementation and/or 
after several hours following intraperitonial lysine injec-
tion (Sauer et al. 2011; Posset et al. 2015). The methods 
used to evaluate lysine degradation metabolites employ 
mass spectrometric platforms that are based on multiple 
sample processing protocols and the use of several types 
of equipment. Typically, PIP is measured by gas chroma-
tography-mass spectrometry (GC–MS) following deri-
vatization of the amine group with methyl chloroformate, 
acidic ethyl acetate extraction and further derivatization 
of the carboxyl group to produce the pentafluorobenzyl 
ester (Kok et al. 1987). SAC, AASA and AAA are usually 
derivatized with fluorenylmethyloxycarbonyl (FMOC) 
chloride and analyzed by liquid chromatography tan-
dem mass spectrometry (LC–MS/MS) performed in a 
triple quadrupole mass spectrometer (Mills et  al. 2006; 
Sadilkova et al. 2009). Alternatively, P6C can be detected 
and quantified without derivatization before LC–MS/MS 
analysis (Struys et al. 2012). Since AASA is in equilibrium 
with P6C, the diagnostic power of measuring either one 
or the other is comparable (Struys et al. 2012). Here, we 
propose a LC–MS/MS approach capable of detecting and 
quantifying all of these metabolites in a single method 
without derivatization. It was our primary interest to val-
idate the method using a lysine-injected mouse model by 
monitoring the time course of lysine-derived metabolite 
levels in peripheral blood.
Methods
Chemicals and reagents
Acetonitrile (ACN) was purchased from J.T. Baker (São 
Paulo, Brazil). Formic acid was obtained from Sigma-
Aldrich (São Paulo, Brazil). All solvents used were high 
performance liquid chromatography (HPLC) grade. Dou-
ble distilled deionized water (here abbreviated simply as 
H2O) was obtained from a Milli-Q purification system 
(Millipore, São Paulo, Brazil). All chemicals and rea-
gents were purchased as of high purity and were stored at 
appropriate temperatures and conditions. The standard 
compounds AAA, SAC, PIP, GLU, l-aspartic acid (ASP), 
l-glutamine (GLN) and pyridoxal-5-phosphate (PLP) 
were obtained from Sigma-Aldrich (St Louis, MO, USA). 
AASA/P6C was prepared from allysine ethylene acetal as 
described (Mills et al. 2006). The internal standards used 
were the deuterated compounds d3-aminoadipic acid 
(D3-AAA) and d9-pipecolic acid (D9-PIP), purchased 
from CDN Isotopes (Pointe-Claire, Quebec, Canada) and 
13C4-Aspatic acid (C13-ASP), purchased from Sigma-
Aldrich (St Louis, USA). Stock solutions of 1  mg/mL 
were prepared for each standard according to manufac-
turers’ instructions. Standard solutions were stored at 
−80 °C.
Analysis of lysine degradation metabolites by LC–MS/MS
High‑performance liquid chromatography (HPLC)
The chromatographic system consisted of an Agilent 
1260 series HPLC with a binary gradient pump. For 
the analytical separation, a Phenomenex Luna PFP (2) 
4.6 × 150.0 mm column with 5.0 µm particles (Alchrom, 
São Paulo, Brazil) was used. Extracts (10  µL) were 
injected into the column, and the analytes eluted at a 
flow rate of 0.8 mL/minute at 30 °C with solvent A (0.1 % 
formic acid in H2O) and solvent B (100  % acetonitrile, 
ACN). The solvent gradient started with 2  % solvent B 
(98 % solvent A) for 1.3 min, followed by a linear increase 
to 60 % B for 7 min, then to 100 % B in 1 min and main-
tained at this concentration for an additional 2 min fol-
lowed by the return to the initial conditions. The total 
run time was 15 min.
Mass spectrometry
The analytes were quantified using an ABSciex 5500 
Qtrap mass spectrometer coupled with TurboV source 
(Concord, Ontario, Canada). Analytes were detected 
using an electrospray ionization detector in positive 
ion mode set at ion spray voltage of 5.5  kV, curtain gas 
of 30  psi, collision gas of 9  eV, temperature of 650  °C, 
nebulizer gas of 70 psi and desolvation gas of 70 psi. For 
instrument tuning, the analytes were diluted with water 
containing 0.1 % formic acid and acetonitrile (1:1, v/v) to 
a final concentration of 50 ng/mL. Analytes were directly 
infused into the ion source using a Harvard syringe at a 
flow rate of 10 µL/minute.
Multiple reactions monitoring (MRM) tuning were 
carried out to optimize fragmentation conditions and 
identify the best precursor/product transitions for quan-
titation and confirmation (Additional file  1: Table S1). 
Scheduled MRM was used with the source parameters 
tuned using flow injection analysis. The predicted struc-
tures of the pairs of precursor and product ions used for 
quantitation are shown in the Additional file 2: Figure S1.
Both instruments and sources were optimized via 
the automatic program, available in the software Ana-
lyst version 1.6.2. The areas of the detected peaks were 
integrated using the algorithm MQ4 from the software 
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MultiQuant 3.0.1. The peak areas of the analytes were 
normalized using those of the corresponding internal 
standards (added to extracts at final working concentra-
tions of 20 ng/mL).
Analytical curves
Calibration curves consisting of nine points per analyte 
were prepared by two-fold serial dilutions of stock solu-
tions of the internal standards (144, 121 and 145  nM 
respectively for D9-PIP, D3-AAA and C13-ASP) to 
achieve the following final range of concentrations: 
AAA: 1.86  μM–7.27  nM; SAC: 1.085  μM–4.24  nM; 
PIP: 2.32  μM–9.07  nM; GLU: 2.04  μM–7.96  nM; ASP: 
2.25  μM–8.8  nM; PLP: 1.23  μM–4.74  nM and P6C: 
2.36  μM–9.22  nM. An artificial plasma solution (Vella 
et al. 2012) containing 10 % bovine serum albumin (BSA) 
was used as a surrogate matrix. Six sets of dilutions were 
prepared independently in the artificial plasma solution 
and processed as following: mixtures were diluted three 
times in ACN, followed by vigorously vortexing and cen-
trifugation at 20,000×g for 15 min at 4 °C. The superna-
tant (ACN extract) was collected and diluted 10 times in 
H2O containing 0.1 % formic acid, and 5 μL were injected 
for the LC–MS/MS analysis.
Animals sampling
Five week old C57BL/6/J female mice were obtained from 
the Multidisciplinary Center for Biological Investigation 
on Laboratory Animal Sciences (CEMIB) of the Univer-
sity of Campinas. Experiments were approved by the Eth-
ics Committee of UNICAMP under the protocol number 
3625-1. Animals were fasted overnight and then intra-
peritoneally injected (IP) with 20  mg of lysine diluted 
in phosphate buffered saline (PBS) or with a solution of 
10 mg of pyridoxine hydrochloride in PBS or PBS only as 
control. Five animals were used per experimental group. 
For the time-course experiment, approximately 50 μL of 
peripheral blood was collected by retro-orbital bleeding 
into EDTA containing tubes at 1, 2, 3, 4 and 6  h post-
injection. As a control, blood samples were collected 
immediately before the lysine injection (0 h). No signifi-
cant changes were observed for the analytes concentra-
tion comparing the 0 h point and PBS injection (data not 
shown).
Metabolite extraction from mouse plasma
Blood was centrifuged at 1500 g for 10 min, and 20 μL of 
plasma was sampled for metabolite extraction. Proteins 
were precipitated and metabolites extracted using ACN 
(2:3), as described in the analytical curves section, con-
taining internal standards to fixed final concentrations 
(144, 121 and 145 nM respectively for D9-PIP, D3-AAA 
and C13-ASP). The supernatants containing the polar 
metabolites were collected, diluted ten times in H2O con-
taining 0.1  % formic acid, and used either immediately 
for LC–MS/MS or stored at −80 °C.
LC–MS/MS method validation
The LC–MS/MS method was validated according to food 
and drug administration (FDA) protocols as discussed 
below (Food Drug Administration Center for Drugs Eval-
uation Research 2013).
Linearity
Calibrations were performed using standards prepared as 
described previously in the section “analytical curves”. Six 
replications of the analytical curves were used to obtain 
the linear equation (y = mx + c).
Limits of detection and quantification
Limits of detection (LOD) and limits of quantification 
(LOQ) were defined as the minimum concentration 
where the signal was at least 3 times and 10 times higher 
than the average background noise at the retention time 
of each analyte, respectively.
Accuracy and reproducibility
The accuracy of the method was determined by estimat-
ing the data dispersion of individual measures of analytes 
to multiple aliquots of the matrix (Food Drug Admin-
istration Center for Drugs Evaluation Research, 2013). 
The intra- and inter-day precisions were evaluated at 
three concentrations: low, median and high (18.8, 37.5 
and 75 ng/ml). Five replicates were run at each level. The 
assay reproducibility was accessed by analyzing three 
data points in the nanomolar range in triplicate on three 
different days. The precision determined at each concen-
tration level did not exceed 15 % of the coefficient of vari-
ation (CV) except for the LOQ, where it did not exceed 
20 % of the CV.
Run stability
Stability at the run time was determined by injecting 
three concentrations in triplicate, directly after sample 
preparation and after a 12  h overnight experiment. The 
samples were kept at 10 °C in the auto-sampler.
Matrix effect
Matrix effect was calculated by using the equation: B/A 
* 100, in which B is the analyte corrected area with IS of 
post-extraction sample and A is the analyte corrected 
area with IS of external solution, in this case, water was 
used. Assays were measured in low and high concentra-
tion and repeated 3 times (Matuszewski et al. 2003).
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Selectivity
The selectivity of an analytical method corresponds to 
the capacity to differentiate and quantify an analyte in the 
presence of other components in the matrix. The selec-
tivity was obtained using MRM and increased using two 
mass filters (quantification and confirmation transitions, 
Additional file  1: Table S1). l-Glutamine (GLN) was 
included to optimize the chromatographic separation in 
the hope to avoid interference with the GLU signal, given 
their similar chemical properties and masses. The PFP(2) 
column provided satisfactory separation also for this 
peak pair.
Results and discussion
LC–MS/MS method development and validation
The LC method was developed to retain all polar ana-
lytes on the column without the need of derivatization. 
Satisfactory retention and separation were obtained 
using the PFP(2) Luna column, composed of pentaflouro-
phenyl groups that can interact with aromatic and polar 
amino acids (Fig.  2). l-Glutamine (GLN) was included 
to optimize the chromatographic separation to avoid 
interference with the GLU signal, given their similar 
chemical properties and masses. The PFP(2) column pro-
vided satisfactory separation also for this peak pair, with 
a selectivity value of 1.2. PIP and D9-PIP displayed a very 
subtle change in the retention time (2.87 and 2.85  min, 
respectively) which is an effect that has been observed in 
other studies as a common result of the isotopic substitu-
tion (Iyer et al. 2004).
The method was validated by analyzing calibration 
standards in sextuplicate for each unlabeled molecule to 
determine linear dynamic range, R2, retention time, LOD, 
and LOQ (Table 1). LODs ranged from to 1.6 to 15 nM 
and LOQs ranged from 6.1 to 25.33  nM. The analysis 
showed correlations (R2) between signal intensity and 
actual analyte concentrations of >0.99 for all standard 
curves (Additional file 3: Figure S2). The analytical curves 
were used to estimate the concentration of each analyte 
in plasma extracts. Table  2 shows the repeatability and 
intermediate precision (%RSD), and accuracy for all ana-
lytes studied. The lowest %RSD value was 2.6 % for PIP 
(medium concentration), and the highest %RSD was 
15.1  % for GLN (low concentrations). Percent RSD val-
ues are in agreement with the accepted values (Boulanger 
et  al. 2005). Accuracy varied from 99.3  % for P6C (low 
concentration) to 104.5  % for PLP (low concentration). 
Matrix effects varied from 3.5  % for AAA at low level 
until 22 % for PLP at low level. These data indicate that 
the developed LC–MS/MS method allows generating 
Fig. 2 Extracted ion LC–MS/MS chromatogram showing the detection of standard analytes at 37 ng/mL. SAC saccharopine, GLN glutamine, ASP 
aspartic acid, C13ASP 13C4 labelled aspartic acid, AAA aminoadipic acid, D3AAA deuterated aminoadipic acid, P6C piperideine-6-carboxylic acid, PIP 
pipecolic acid, D9PIP deuterated pipecolic acid, PLP pyridoxal-5-phosphate
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high confidence results. Statistical analysis using one-
way ANOVA showed that there were no significant 
differences between days in which experiments were 
performed. Molecules were stable for 12  h in the auto-
sampler at 10 °C.
Time‑course analysis of lysine metabolites in mice plasma
A time-course experiment using 5  week old C57BL/6/J 
mice was performed with 5 animals per treatment. A 
PBS solution containing 20 mg of l-lysine, pH 7, was IP 
injected into each animal, and small aliquots of venous 
blood were taken at 1 h intervals for 6 h. Control IP injec-
tions of PBS solution did not influence the levels of the 
lysine degradation metabolites (data not shown) and did 
not differ statistically from the concentrations found at 
zero time point. Samples were processed for metabolite 
extraction from plasma and analyzed using the developed 
LC–MS/MS method.
Table 1 LC-MS/MS method validation parameters
The linear equation represents the relation between the area ratio (peak area of analyte divided by peak area of IS) and ηg mL−1  concentration
LOD limit of detection, LOQ limit of quantification




Linear equation R2 Retention  
time (min)
LOD (ηM) LOQ (ηM)
l-Amino adipic acid 7.2–1860 1.17–300 y = 0.0911x + 0.0167 0.995 2.4 1.86 6.20
l-saccharopine 33.9–1085 9.3–300 y = 0.0215x + 0.0042 0.995 2.1 7.60 25.33
l-Pipecolic acid 9.07–2322 1.17–300 y = 0.0366x + 0.0008 0.999 2.9 2.32 7.74
l-Glutamic acid 7.96–2039 1.17–300 y = 0.0789x + 0.0545 0.995 2.2 2.03 6.11
Pyridoxal phosphate 37.9–1213 9.3–300 y = 0.0011x + 0.0020 0.996 4.8 14.97 36.4
Piperideine-6- 
carboxylic acid
9.2–2359 1.17–300 y = 0.0203x + 0.0053 0.998 2.4 2.35 19.6
Table 2 Method performance as  measured in  two consecutive days with  three different concentrations of  metabolites 
(low, medium and high)
The calculated concentrations, %RSD and %CV were obtained using MultiQuant 3.0.1 software (ABSciex)
Compound Theoretical  
concentration
ng mL−1
Intraday precision  
(n = 5)
(mean ± S.D.)




l-Amino adipic acid 18.8 19.1 ± 3.1 19.2 ± 2.2 11.7 99.9
37.5 36.3 ± 2.1 39.1 ± 4.8 12.4 99.9
75 75.9 ± 8.47 75.8 ± 6.5 10.5 100.0
l-Saccharopine 18.8 20.3 ± 2.8 19.1 ± 2.5 13.1 99.8
37.5 38.4 ± 3.8 37.5 ± 4.8 12.7 99.7
75 71.9 ± 5.1 71.1 ± 5.9 12.3 99.8
l-Pipecolic acid 18.8 19.1 ± 1.4 19.1 ± 0.97 5.1 100.0
37.5 37.5 ± 0.8 37.4 ± 0.95 2.6 100.1
75 76.4 ± 8.6 75.1 ± 4.3 5.7 100.0
l-Glutamic acid 18.8 18.7 ± 1.7 18.6 ± 1.6 8.6 100.0
37.5 35.4 ± 2.1 37.5 ± 3.1 8.3 99.9
75 72.3 ± 5.7 74.7 ± 5.3 7.1 99.9
l-Glutamine 18.8 20.1 ± 3.8 19.5 ± 2.9 15.1 99.9
37.5 38.5 ± 4.3 37.6 ± 4.4 11.7 99.7
75 73.7 ± 5.8 73.7 ± 8.7 8.8 99.9
Pyridoxal phosphate 18.8 18.2 ± 1.5 18.7 ± 1.6 8.4 104.0
37.5 36.2 ± 1.9 37.9 ± 2.7 7.1 100.0
75 73.5 ± 6.1 75.7 ± 4.8 6.4 100.1
Piperideine-6-carboxylic acid 18.8 18.5 ± 1.31 19.5 ± 1.4 5.6 99.3
37.5 36.4 ± 1.2 37.53 ± 0.8 7.8 100.6
75 74.1 ± 8.6 76.6 ± 5.4 7.9 99.9
Page 7 of 9Pena et al. SpringerPlus  (2016) 5:172 
The principal metabolite of lysine degradation detected 
in the mice plasma was AAA, which reached a peak of 
approximately 70  μM in the plasma 1  h after IP lysine 
injection (Fig.  3a). This value represents a 24-fold 
increase compared to the basal AAA values seen at zero 
time point that was estimated at approximately 3  μM. 
This value is similar to the 4 μM basal AAA concentra-
tion found in normal mouse plasma, as reported in the 
mouse multiple tissue metabolome database (MMMDB) 
(Sugimoto et  al. 2012) and in the human metabolome 
database (HMDB 2.0) (Vallat et  al. 1996; Wishart et  al. 
2013) These results suggest that lysine is rapidly oxi-
dized to AAA reaching a maximum within the first 2  h 
after lysine administration. Four to 6 h following IP lysine 
injection, AAA returned to concentrations that were not 
statistically different from that observed for zero time 
point.
The levels of SAC and PIP (Fig.  3b, c, respectively) 
followed the same pattern of AAA with highest levels 
within the first two hours after IP lysine injection. The 
basal levels of SAC in the mice and human plasma are 
not listed in the MMMDB or HMDB and thus we could 
not compare these to the present values. The basal 
levels of PIP in mice and human plasma as shown in 
MMMDB (Sugimoto et al. 2012) and HMDB (Baas et al. 
2002; Kok et al. 1987) varies from 3.5 to 10.8 μM. These 
values are in the same range of the PIP concentration 
(4.9  μM) we found at zero time point. The P6C levels 
showed similar tendency as the pattern observed for 
AAA, SAC and PIP but the increased signal detected 
after 2  h IP lysine injection was not statistically sig-
nificant (Fig. 3d). The P6C basal levels found in mouse 
plasma ranged from 0.1 to 0.38 μM, which are similar 
to the basal levels found in human plasma (Sadilkova 
et  al. 2009). These results suggest that the AASADH 
enzyme rapidly converts P6C into AAA. It is also pos-
sible that the subsequent reaction steps of lysine deg-
radation are slower than the initial steps favoring the 
accumulation of AAA in the blood within the first 2 h 
of IP lysine injection.
We also measured the levels of GLU in plasma of the 
IP lysine injected mice (Fig. 3e) as it is a direct product 
of saccharopine pathway. GLU is produced by transami-
nation like reaction in with the ε nitrogen of lysine is 
transferred to α-ketoglutarate during the saccharopine 
hydrolysis catalyzed by the SDH enzyme. It would be 
expected that GLU levels would increase after IP lysine 
injection, but this was not observed. On the other hand, 
the levels of GLN remained high, and no significant 
change was observed during the time-course analy-
sis (Fig.  3f ). The observed average basal levels of GLU 
(~55  μM) and GLN (~610  μM) were also within the 
basal concentration ranges observed in the MMMDB 
(GLU  ~  25  μM, GLN  ~  400  μM) and the HMDB 
(GLU ~ 20–100 μM, GLN ~ 490–650 μM).
Absorption of vitamin B6 occurs mainly in the form of 
pyridoxine, pyridoxal, and pyridoxamine and in the liver 
these compounds are converted by the enzyme pyridoxal 
kinase into 5′-phosphate derivatives. Pyridoxamine-
5-phosphate and pyridoxine-5-phosphate are then con-
verted to PLP by the enzyme pyridoxamine phosphate 
oxidase (PNPO) (Mills et  al. 2011). We tested IP injec-
tion of pyridoxine hydrochloride into mice to determine 
if increased levels of free PLP are seen at the same time 
that AAA is produced from lysine catabolism. The levels 
of free PLP detected during the time-course experiment 
(Fig.  4) showed that this metabolite was also increased 






Time after injection (h) Time after injection (h)
Time after injection (h) Time after injection (h)














Fc = 24 x Fc = 3.6 x
Fc = 2.7 xFc = 16 x






























































































Fc = 3 x
Fc = 2 x
Fig. 3 Time-course analysis of lysine degradation metabolites in 
mouse plasma after IP injection of 20 mg lysine. Fc = fold change as 
compared to basal concentrations (time 0). Asterisks represent statisti-
cally significant differences at p < 0.05 (Student’s T Test)
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during the first hour after injection, similar to the 
observed pattern of lysine degradation metabolites.
Conclusions
We developed a LC–MS/MS method capable of simul-
taneous detection of the relevant metabolites of lysine 
catabolism via aminoadipate using a single MS-instru-
ment. The method did not detect AASA but since this 
compound is in chemical equilibrium with its cyclic 
form P6C, the detection of the latter is highly correlated 
to AASA levels (Struys et  al. 2012). The quantifications 
of AAA, SAC, and PIP basal levels were consistent with 
the basal plasma values listed in the mice MMMDB 
and human HMDB databases. A time-course analysis 
of lysine degradation metabolites in mice blood after IP 
lysine injection revealed that lysine degradation to AAA 
is a fast process, with a maximum rate occurring within 
the first 2 h after lysine treatment. This experiment was 
used to validate the method and, in addition, revealed 
that lysine degradation occurs at a fast rate, and the lev-
els of catabolites return to basal levels after 4–6 h lysine 
treatment. The method was also used to detect the levels 
of PLP after IP injection of pyridoxine. The production 
of PLP from pyridoxine reached a maximum within 2 h 
treatment with pyridoxine, similarly to what is observed 
for the lysine catabolites. This finding may be relevant 
for PDE since the accumulated P6C may react with PLP 
just after dietary intake of lysine and pyridoxine. Finally, 
we suggest that the method developed here which allows 
simultaneous analysis of lysine degradation metabolites 
would be useful in investigations of diseases such as PDE, 
in which this pathway is perturbed.
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Fig. 4 Time-course analysis of pyridoxal-5-phosphate in mouse 
plasma after IP injection of 10 mg pyridoxine hydrochloride
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